Epiretinal Membrane
Conditions
Brief summary
The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.
Interventions
monthly injections x3 +/- 2nd series of 3
Sponsors
Queen's University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* symptomatic idiopathic epiretinal membrane
Exclusion criteria
* vision worse than 6/18 and fit for surgery * prior vitreoretinal surgery or injection * diabetes * any past or current form of retinal vein occlusion or neovascularization * age-related macular degeneration * other condition causing significant limitation of visual potential
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evidence of improvement measured by optical coherence tomography | 3 and 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Distance visual acuity (ETDRS) | 3 and 6 months |
| Near visual acuity (Snellen) | 3 and 6 months |
| Subjective change in symptoms | 3 and 6 months |
| Amsler grid improvement | 3 and 6 months |
| Quality of life improvement | 6 months |
Countries
Canada
Outcome results
None listed